tiprankstipranks
Marinomed Biotech AG (DE:93Z)
FRANKFURT:93Z
Germany Market
93Z
Marinomed Biotech AG
RESEARCH TOOLSreports
Want to see DE:93Z full AI Analyst Report?

Marinomed Biotech AG (93Z) Ratios

0 Followers

Marinomed Biotech AG Ratios

DE:93Z's free cash flow for Q2 2024 was €0.40. For the 2024 fiscal year, DE:93Z's free cash flow was decreased by € and operating cash flow was €-0.80. See a summary of the company’s cash flow.
Ratios
TTM
Mar 24Mar 23Dec 21Dec 20
Liquidity Ratios
Current Ratio
 0.21 0.74 2.40 2.14 2.75
Quick Ratio
 0.21 0.63 2.13 1.97 2.58
Cash Ratio
 0.16 0.27 1.37 0.96 1.64
Solvency Ratio
 1.22 -0.25 -0.22 -0.25 -0.31
Operating Cash Flow Ratio
 -0.75 -0.47 -0.87 -0.81 -1.23
Short-Term Operating Cash Flow Coverage
 -0.54 -0.65 -2.13 -6.45 -19.30
Net Current Asset Value
€ -11.47M€ -17.61M€ -12.18M€ -8.27M€ -2.75M
Leverage Ratios
Debt-to-Assets Ratio
 1.93 1.49 1.02 0.74 0.55
Debt-to-Equity Ratio
 -1.16 -2.15 -5.44 82.54 2.39
Debt-to-Capital Ratio
 7.13 1.87 1.23 0.99 0.71
Long-Term Debt-to-Capital Ratio
 -1.62 3.15 1.26 0.99 0.70
Financial Leverage Ratio
 -0.60 -1.44 -5.36 111.48 4.39
Debt Service Coverage Ratio
 1.81 -0.43 -0.65 -1.67 -4.55
Interest Coverage Ratio
 37.40 -3.71 -2.29 -2.75 -9.75
Debt to Market Cap
 0.53 0.49 0.27 0.12 0.07
Interest Debt Per Share
 6.47 15.27 16.77 11.73 9.19
Net Debt to EBITDA
 0.56 -5.30 -4.50 -2.80 -0.74
Profitability Margins
Gross Profit Margin
25.97%12.45%18.98%12.25%-7.90%
EBIT Margin
242.86%-46.83%-34.43%-35.99%-65.15%
EBITDA Margin
246.75%-39.45%-28.49%-30.76%-59.88%
Operating Profit Margin
242.86%-55.85%-51.01%-35.64%-85.68%
Pretax Profit Margin
235.06%-73.95%-56.68%-48.97%-73.93%
Net Profit Margin
198.70%-73.99%-56.74%-50.67%-73.98%
Continuous Operations Profit Margin
197.40%-73.99%-56.74%-50.67%-73.98%
Net Income Per EBT
84.53%100.06%100.11%103.46%100.06%
EBT Per EBIT
96.79%132.39%111.12%137.39%86.29%
Return on Assets (ROA)
259.32%-46.50%-28.71%-27.61%-25.57%
Return on Equity (ROE)
-85.10%67.03%153.90%-3078.00%-112.18%
Return on Capital Employed (ROCE)
-10900.42%-103.44%-35.22%-27.05%-38.90%
Return on Invested Capital (ROIC)
293.20%-43.05%-34.83%-25.75%-38.12%
Return on Tangible Assets
259.97%-51.92%-31.24%-30.48%-28.03%
Earnings Yield
60.70%-15.33%-7.57%-4.54%-3.43%
Efficiency Ratios
Receivables Turnover
 23.03 3.85 3.61 2.42 1.57
Payables Turnover
 36.14 5.25 7.92 5.11 4.44
Inventory Turnover
 5.13K 7.94 5.85 9.93 9.47
Fixed Asset Turnover
 1.71 1.54 1.82 1.81 1.35
Asset Turnover
 1.31 0.63 0.51 0.54 0.35
Working Capital Turnover Ratio
 -0.44 3.17 1.49 1.40 0.77
Cash Conversion Cycle
 5.82 71.21 117.49 116.46 189.16
Days of Sales Outstanding
 15.85 94.77 101.15 151.06 232.87
Days of Inventory Outstanding
 0.07 45.96 62.41 36.76 38.56
Days of Payables Outstanding
 10.10 69.51 46.08 71.36 82.27
Operating Cycle
 15.92 140.73 163.57 187.82 271.43
Cash Flow Ratios
Operating Cash Flow Per Share
 -2.46 -2.98 -3.47 -3.30 -4.68
Free Cash Flow Per Share
 -2.53 -3.07 -3.62 -3.92 -7.37
CapEx Per Share
 0.07 0.08 0.15 0.62 2.69
Free Cash Flow to Operating Cash Flow
 1.03 1.03 1.04 1.19 1.58
Dividend Paid and CapEx Coverage Ratio
 -35.24 -35.24 -22.86 -5.30 -1.74
Capital Expenditure Coverage Ratio
 -35.24 -35.24 -22.86 -5.30 -1.74
Operating Cash Flow Coverage Ratio
 -0.40 -0.21 -0.23 -0.31 -0.54
Operating Cash Flow to Sales Ratio
 -0.59 -0.49 -0.46 -0.42 -0.85
Free Cash Flow Yield
-17.00%-10.50%-6.42%-4.45%-6.20%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 1.65 -6.52 -13.21 -22.05 -29.13
Price-to-Sales (P/S) Ratio
 3.56 4.83 7.50 11.17 21.55
Price-to-Book (P/B) Ratio
 -2.57 -4.37 -20.34 678.55 32.68
Price-to-Free Cash Flow (P/FCF) Ratio
 -5.88 -9.52 -15.57 -22.45 -16.14
Price-to-Operating Cash Flow Ratio
 -5.57 -9.79 -16.25 -26.69 -25.43
Price-to-Earnings Growth (PEG) Ratio
 0.02 -1.33 -1.88 9.02 1.48
Price-to-Fair Value
 -2.57 -4.37 -20.34 678.55 32.68
Enterprise Value Multiple
 1.99 -17.54 -30.81 -39.11 -36.73
Enterprise Value
 37.98M 63.54M 98.99M 139.87M 178.69M
EV to EBITDA
 2.00 -17.54 -30.81 -39.11 -36.73
EV to Sales
 4.93 6.92 8.78 12.03 21.99
EV to Free Cash Flow
 -8.16 -13.64 -18.23 -24.18 -16.47
EV to Operating Cash Flow
 -8.39 -14.03 -19.03 -28.74 -25.95
Tangible Book Value Per Share
 -3.74 -7.68 -3.98 -1.23 2.24
Shareholders’ Equity Per Share
 -5.33 -6.68 -2.77 0.13 3.64
Tax and Other Ratios
Effective Tax Rate
 0.16 >-0.01 >-0.01 -0.03 >-0.01
Revenue Per Share
 4.18 6.05 7.52 7.88 5.52
Net Income Per Share
 8.32 -4.48 -4.27 -3.99 -4.09
Tax Burden
 0.85 1.00 1.00 1.03 1.00
Interest Burden
 0.97 1.58 1.65 1.36 1.13
Research & Development to Revenue
 0.00 0.00 0.61 0.65 0.73
SG&A to Revenue
 0.36 0.11 0.12 0.09 0.13
Stock-Based Compensation to Revenue
 0.00 0.00 0.00 0.00 0.00
Income Quality
 0.67 0.67 0.81 0.83 1.15
Currency in EUR